CD20 Positive

11 clinical trials · Condition

Record	Firm	Date
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (NCT03946878)	M.D. Anderson Cancer Center	2019-08-13
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma (NCT03704714)	Northwestern University	2018-11-20
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma (NCT02532257)	M.D. Anderson Cancer Center	2016-04-11
Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (NCT02219737)	National Cancer Institute (NCI)	2014-09-12
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma (NCT01959698)	Roswell Park Cancer Institute	2014-04-17
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma (NCT01880567)	M.D. Anderson Cancer Center	2013-07-15
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (NCT01729806)	National Cancer Institute (NCI)	2012-11-19
Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (NCT01363128)	M.D. Anderson Cancer Center	2011-07-12
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant (NCT00880815)	M.D. Anderson Cancer Center	2009-02-17

Track CD20 Positive automatically

Every clearance here is in the API, with alerts when new ones post.